ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-OR016

Clinical Outcomes and Disparities Associated with ESKD due to AKI in the United States

Session Information

Category: Acute Kidney Injury

  • 102 AKI: Clinical, Outcomes, and Trials


  • Shah, Silvi, University of Cincinnati, Cincinnati, Ohio, United States
  • Leonard, Anthony C., University of Cincinnati, Cincinnati, Ohio, United States
  • Meganathan, Karthikeyan, University of Cincinnati, Cincinnati, Ohio, United States
  • Christianson, Annette, Cincinnati VA, Cincinnati, Ohio, United States
  • Thakar, Charuhas V., University of Cincinnati, Cincinnati, Ohio, United States

Acute kidney injury (AKI) is associated with increased mortality. Mortality in end-stage kidney disease (ESKD) patients is highest during the first year of dialysis. ESKD due to AKI is common, but little is known about the rate of recovery and its impact on long-term outcomes in incident dialysis patients.


We evaluated a retrospective cohort of 1,045,540 incident ESKD patients from the United States Renal Data System. Using Cox proportional hazard models, we examined the impact of AKI as the ESKD cause on the primary outcome of all-cause mortality. Additionally, we determined the impact of sex and race on renal recovery and associated mortality in patients with AKI as the ESKD cause.


Mean age was 63±15 years. Of the study cohort, 3.3% had ESKD due to AKI. The majority were men (58.1%) and white (75.8%). One-year all-cause mortality was 21.8%. Compared to ESKD due to diabetes (46% of the sample, the most common cause), ESKD due to AKI was associated with changes in the adjusted mortality across the follow-up period – higher adjusted hazards of mortality in first 0-3 months following dialysis initiation (HR, 1.27; 95% CI, 1.23-1.31) and 3-6 months (HR, 1.15; 95% CI, 1.11-1.20), followed by lower adjusted hazards of mortality at 6-12 months (HR, 0.93; 95% CI, 0.90-0.97) that continued to decrease through 84-96 months of follow up (HR, 0.46; 95% CI, 0.41-0.52). Of the patients with ESKD due to AKI, 35.3% eventually recovered their kidney function. The median time of recovery was 2 months (IQR, 1.2-3.5 months). Women had lower adjusted hazards of renal recovery than did men (HR, 0.86; 95% CI, 0.82-0.89). As compared to whites, blacks (HR, 0.67; 95% CI, 0.65-0.71), Asians (HR, 0.77; 95% CI, 0.66-0.90), and Hispanics (HR, 0.80; 95% CI, 0.74-0.86) had a lower likelihood of renal recovery. Heart failure and diabetes were other risk factors associated with non-recovery.


About one-third of patients with ESKD due to AKI recover kidney function. Mortality risk changes across the follow-up period in patients with ESKD due to AKI. Women have a 14% lower likelihood of recovery than men. Black, Asian, and Hispanic patients have a lower likelihood of recovery than do white patients. The study suggests that the need for customized dialysis care in patients with ESKD due to AKI.